EUCTR2009-017664-16-FR进行中（未招募）不适用
GIANT Study - Genotyping Infarct patients to Adjust and Normalize Thienopyridine treatment - GIANT
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- STEMI patient treated by primary PCI (with stent implantation) within the 24 hours following first chest pain
- •- age above 18 years old
- •- Informed consent has to be signed by the patient
- •- Patient available to perform the 1year-follow up visit
- •- Patient covered by French Health Care system
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- NONSTEMI patient with high troponin
- •- STEMI patient not treated in the first 24 hours following chest pain
- •- Stable or unstable angina or silent ischemia
- •- Cardiogenic shock
- •- Patient under AVK treatment
- •- Contra-indication for PCI
- •- Age under 18 years old
- •- Participation in another clinical trial
- •- Pregnancy / planification of pregnancy
- •- Known allergy to media contrast that can not be controlled by an adapted treatment
- •- Known allergy to Cobalt Chromium alloy
- •- LVEF < 30%
研究者
相似试验
招募中
不适用
The PersOnalising gEneTIc Counselling (POETIC) Trial: Testing the implementation and effectiveness of an intervention to personalise genetic counsellingInherited predisposition to cancerHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersCancer - Any cancerACTRN12621001582842Peter MacCallum Cancer Centre246
已完成
4 期
Genetic-Disease Outcome Consortium-Aliskiren StudyHypertension with Diabetes MellitusJPRN-UMIN000005612GENOMIC DISEASE OUTCOME CONSORTIUM (G-DOC) STUDY INVESTIGATORS100
进行中（未招募）
不适用
A clinical trial for the comparison of two anaesthetic creams.Pain related to the cannulation of arteriovenous fistula cannulation in haemodialysis patients.EUCTR2012-004993-25-GRVerisfield (UK) Ltd
已完成
不适用
Human genome analysis project to identify risk factors of HBV reactivation following rituximab plus steroids containing chemotherapy (C-SHOT1402)Malignant lymphomaJPRN-UMIN000016177The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine/Department of Human Genetics, Graduate School of Medicine, University of Tokyo200
进行中（未招募）
1 期
Biomarkers of Response to Pembrolizumab Combined with Chemotherapy in Non-Small Cell Lung Cancer (Keynote-782)EUCTR2018-002598-22-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100